Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ether doai
Patent
1996-06-03
1997-11-25
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ether doai
A61K 3108
Patent
active
056913877
ABSTRACT:
The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
REFERENCES:
patent: 2674619 (1954-04-01), Lundsted
patent: 2854378 (1958-09-01), Buckwalter et al.
patent: 3089818 (1963-05-01), Stone
patent: 3140232 (1964-07-01), Noseworthy
patent: 3450502 (1969-06-01), Hymes
patent: 3577522 (1971-05-01), Hymes
patent: 3590125 (1971-06-01), Hymes
patent: 3641240 (1972-02-01), Hymes et al.
patent: 3740421 (1973-06-01), Schmolka
patent: 3867521 (1975-02-01), Miskel et al.
patent: 3956259 (1976-05-01), Garcia et al.
patent: 3980772 (1976-09-01), Ginger et al.
patent: 4073886 (1978-02-01), Kehm
patent: 4100271 (1978-07-01), Krezanoski
patent: 4179337 (1979-12-01), Davis et al.
patent: 4186253 (1980-01-01), Yokoyama et al.
patent: 4305922 (1981-12-01), Rhodes
patent: 4395393 (1983-07-01), Schmolka
patent: 4407790 (1983-10-01), Oakes et al.
patent: 4600652 (1986-07-01), Solomon et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4764567 (1988-08-01), Ott
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4837083 (1989-06-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4897263 (1990-01-01), Hunter
patent: 4937070 (1990-06-01), Hunter
patent: 4997644 (1991-03-01), Hunter
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
patent: 5198211 (1993-03-01), Hunter et al.
patent: 5294365 (1994-03-01), Welch et al.
patent: 5340916 (1994-08-01), Henn et al.
patent: 5371253 (1994-12-01), Cooper
patent: 5523492 (1996-06-01), Emanuele et al.
Schmolka, I., "A Review of Block Polymer Surfactants," Journal of the American Oil Chemists Society, 54, No. 3, pp. 110-116 (1977).
Block and Graft Copolymerization, vol. 2, (ed. by R.J. Ceresa, John Wiley & Sons, 1976) "The Applications of Block Copolymer Polyol Surfactants, " L.G. Lundsted and I.R. Schmolka; pp. 174-205 and pp. 255-272 (reference).
Reindorf. C.A., et al., "Perfluorocarbon Compounds: Effects on the Rheological Properties of Sickle Erythrocytes in vitro," American Journal of Hematology, vol. 19, pp. 229-236 (1985).
Padilla, F., et al., "Effect of Fluoricarbon Emulsions on the Mechanical Fragility of Normal and Sickle Cells: In Vitro Studies," Federation Proceedings, vol. 34, pp. 1510-1512 (1975).
Vercellotti, G.M., et al., "Activation of Plasma Complement by Perfluorocarbon Artificial Blood: Probable Mechanism of Adverse Pulmonary Reactions in Treated Patients and Rationale for Corticosteroid Prophylaxis," Blood, vol. 59, pp. 1299-1304 (1982).
Rodeheaver, G.T., "Pluronic.RTM. F-68: A Promising New Skin Wound Cleaner," Ann Emerg Med, 9:11, pp. 572-576 (1980).
Janoff, A.S., et al., "The Modification of Human Erythrocyte Membrane Structure by Membrane Stabilizers: An Electron Spin Resonance Study," American Journal of Hematology, vol. 10, pp. 171-179 (1981).
Moore, A.R., et al., "Reduction of Splenic Vascular Resistance During Profusion by Pluronic.RTM. F-68," Journal of Surgical Research, vol. 8, pp. 563-566 (1968).
Benner, K.U., et al., "Cold-Induced Platelet Aggregation In Vivo And Its Inhibition By A Nonionic Surface Active Substance," Thrombosis Research, vol. 2, pp. 331-342 (1973).
Hymes, A.C., et al., "The Influence Of An Industrial Surfactant Pluronic.RTM. F-68, In The Treatment of Hemorrhagic Shock," Journal of Surgical Research, vol. 11, pp. 191-197 (1971).
Hoie, J., et al., "Effects of Pluronic.RTM. F68, Poloralkol, On Vascular Resistance In Vivo," Journal of Surgical Research, vol. 11, pp. 515-517 (1971).
Grover, F.L., et al., "A Nonionic Surfactant And Blood Viscosity," Arch Surg., vol. 106, pp. 307-310 (1973).
Grover, F.L., et al., "The Effect of Pluronic.RTM.F-68 On Circulatory Dynamics And Renal And Carotid Artery Flow During Hemorrhagic Shock," Journal of Surgical Research, vol. 17, pp. 30-35 (1974).
Ketchum, L.D., et al., "Experimental Use of Pluronic.RTM. F-68 In Microvascular Surgery," Plastic and Reconstructive Surgery, vol. 53, pp. 288-292 (1974).
Ketchum, L.D., "Pharmacological alternations in the clotting mechanism: Use in microvascular surgery," Journal of Hand Surgery, vol. 3, pp. 407-415 (1978).
Vasko, K.A., et al., "Poloxalkol.RTM. (Pluronic F-68): A priming solution for cardiopulmonary bypass," Trans. Am. Soc. Artif. Int. Organs, 18, pp. 526-531 (1972).
Block, N.L., et al., "Acutely Traumatized Canine Ureter, Effects of Low Molecular Weight Dextran and Surfactant Pluronic F-68," Urology, vol. III, pp. 190-194 (1974).
Knize, D.M., et al., "Use of antisludging agents in experimental cold injuries," Surgery, Gynecology & Obstetrics, vol. 129, pp. 1019-1026 (1969).
Organ Perfusion and Preservation, (ed. by Norman, J.C., Appleton-Century-Crofts, (1968)), Paton, B.C., et al., "The use of a nonionic detergent added to organ perfusates," pp. 105-120.
Smillie, J.A., et al., "Cryopreservation of Human Platelets with Polyvinylpyrrolidone," Transfusion, vol. 21, pp. 552-556 (1981).
Gaehtgens, P., et al., "Desaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis," Acta Heamat, vol. 33, pp. 82-89 (1975).
Advances in Blood Substitute Research (ed. by Bolin, et al., Alan R. Liss, Inc. New York (1983)) Sugi, et al., The Use of Fluosol-DA (FDA) in Emergency Situations: A Report of 67 Clinical Cases, Abstract/451.
Lane, T.A., et al., "Reduction in the Toxicity of a Component of an Artificial Blood Substitute by supercritical fluid fractionation," Transfusion, vol. 28, pp. 375-378 (1987).
Lane, T.A., et al., "Paralysis of Phagocyte Migration Due to an Artificial Blood Substitute," Blood, vol. 64, pp. 400-405 (1984).
Spiess, B.D., et al., "Protection from Cerebral Air Emboli with Perfluorocarbons in Rabbits," Stroke, vol. 17, pp. 1146-1149 (1986).
Kanter, K.R., et al., "Superiority of Perfluorocarbon Cardioplegia over Blood or Crystalloid Cardioplegia," Circulation, vol. 64, pp. II-75-II-80 (1981).
Harjula, A., et al., "Perfluorocarbon solution as a myocardial preservative," J. Applied Cardiology, vol. 2, pp. 121-136 (1987).
Tokioka, M.D., et al., "Effects of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions," Laboratory Investigation, vol. 75, pp. 473-481 (1987).
Forman, M.B., et al., "Reduction of Infarct Size with Intracoronary Perfluorochemical in a Canine Preparation of Reperfusion," Circulation, vol. 71, pp. 1060-1068 (1985).
Forman, M.B., et al., "Beneficial Long-Term Effect of Intracoronary Perfluorochemical on Infarct Size and Ventricular Function in a Canine Reperfusion Model," J. Am. Col. of Cardiol., pp. 1082-1090 (May 1987).
Goodman, R.L., et al., "Perfluorocarbon Emulsions in Cancer Therapy: Preliminary Observations on Presently Available Formulations," Int. J. Radiation Oncology Biol. Phys., vol. 10, pp. 1421-1424 (1984).
Grover et al., "A Nonionic Surfactant and Blood Viscosity-Experimental Observations," Arch. Surg., vol. 106, pp. 307-310 (Mar. 1973).
Connaghan et al., "Specific Identification of Fibrin Polymers, Fibrinogen Degradation Products, and Crosslinked Fibrin Degration Products in Plasma and Serum With a New Sensitive Technique," Blood, vol. 65, No. 3, pp. 589-597
Culbreth Paula H.
Emanuele R. Martin
Hunter Robert L.
Cytrx Corporation
Peabody John
Richter Johann
LandOfFree
Polyoxypropylene/polyoxyethylene copolmers with improved biologi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyoxypropylene/polyoxyethylene copolmers with improved biologi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyoxypropylene/polyoxyethylene copolmers with improved biologi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2107563